Preliminary results from a small clinical trial of a 2009 influenza A(H1N1) vaccine indicate that a single dose may protect most healthy pregnant women.
Pregnant women appear to be among the most vulnerable to complications from the currently circulating influenza strain, with at least 100 pregnant women being hospitalized and 28 dying from such infections since the outbreak began in the spring, according to the US Centers for Disease Control and Prevention. For this reason, they are a high-priority group for vaccination. So far, results from a subgroup of 50 pregnant women enrolled in a clinical trial of the vaccine produced by Sanofi Pasteur at its Pennsylvania facility suggest that a single dose will protect more than 90% of the women from infection. More information about the trial, which is funded by the National Institute of Allergy and Infectious Diseases, is available on the institute's Web site (http://www3.niaid.nih.gov/news/QA/H1N1pregnanttrials.htm).
Kuehn BM. One Shot. JAMA. 2009;302(24):2644. doi:10.1001/jama.2009.1850